{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T09:52:46Z","timestamp":1788774766592,"version":"build-2803163510"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,2,15]],"date-time":"2021-02-15T00:00:00Z","timestamp":1613347200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,2,15]],"date-time":"2021-02-15T00:00:00Z","timestamp":1613347200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["U01EB012495"],"award-info":[{"award-number":["U01EB012495"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["ILET2"],"award-info":[{"award-number":["ILET2"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Deliv. and Transl. Res."],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1007\/s13346-021-00927-4","type":"journal-article","created":{"date-parts":[[2021,2,18]],"date-time":"2021-02-18T22:51:41Z","timestamp":1613688701000},"page":"692-701","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Fabrication of microneedle patches with lyophilized influenza vaccine suspended in organic solvent"],"prefix":"10.1007","volume":"11","author":[{"given":"Yoo Chun","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong Woo","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. Stein","family":"Esser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haripriya","family":"Kalluri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica C.","family":"Joyce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard W.","family":"Compans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioanna","family":"Skountzou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9076-8448","authenticated-orcid":false,"given":"Mark R.","family":"Prausnitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,15]]},"reference":[{"issue":"1","key":"927_CR1","doi-asserted-by":"publisher","first-page":"e25","DOI":"10.1016\/S1473-3099(17)30360-2","volume":"18","author":"A Singanayagam","year":"2018","unstructured":"Singanayagam A, Zambon M, Lalvani A, Barclay W. Urgent challenges in implementing live attenuated influenza vaccine. Lancet Infect Dis. 2018;18(1):e25\u201332. https:\/\/doi.org\/10.1016\/S1473-3099(17)30360-2.","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"927_CR2","doi-asserted-by":"publisher","first-page":"66","DOI":"10.3390\/pathogens5040066","volume":"5","author":"PR Saunders-Hastings","year":"2016","unstructured":"Saunders-Hastings PR, Krewski D. Reviewing the history of pandemic influenza: understanding patterns of emergence and transmission. Pathogens. 2016;5(4):66. https:\/\/doi.org\/10.3390\/pathogens5040066.","journal-title":"Pathogens."},{"issue":"26","key":"927_CR3","doi-asserted-by":"publisher","first-page":"3003","DOI":"10.1016\/j.vaccine.2015.02.042","volume":"33","author":"IM Foppa","year":"2015","unstructured":"Foppa IM, Cheng PY, Reynolds SB, Shay DK, Carias C, Bresee JS, et al. Deaths averted by influenza vaccination in the US during the seasons 2005\/06 through 2013\/14. Vaccine. 2015;33(26):3003\u20139. https:\/\/doi.org\/10.1016\/j.vaccine.2015.02.042.","journal-title":"Vaccine"},{"issue":"48","key":"927_CR4","doi-asserted-by":"publisher","first-page":"6369","DOI":"10.1016\/j.vaccine.2014.07.012","volume":"32","author":"A Palache","year":"2014","unstructured":"Palache A, Oriol-Mathieu V, Abelin A, Music T. Influenza Vaccine Supply task f. Seasonal influenza vaccine dose distribution in 157 countries (2004\u20132011). Vaccine. 2014;32(48):6369\u201376. https:\/\/doi.org\/10.1016\/j.vaccine.2014.07.012.","journal-title":"Vaccine."},{"issue":"11","key":"927_CR5","doi-asserted-by":"publisher","first-page":"e0164692","DOI":"10.1371\/journal.pone.0164692","volume":"11","author":"A Flood","year":"2016","unstructured":"Flood A, Estrada M, McAdams D, Ji Y, Chen D. Development of a freeze-dried, heat-stable influenza subunit vaccine formulation. PLoS One. 2016;11(11):e0164692. https:\/\/doi.org\/10.1371\/journal.pone.0164692.","journal-title":"PLoS One"},{"issue":"4","key":"927_CR6","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.vaccine.2005.07.081","volume":"24","author":"F Coenen","year":"2006","unstructured":"Coenen F, Tolboom JT, Frijlink HW. Stability of influenza sub-unit vaccine. Does a couple of days outside the refrigerator matter? Vaccine. 2006;24(4):525\u201331. https:\/\/doi.org\/10.1016\/j.vaccine.2005.07.081.","journal-title":"Vaccine."},{"issue":"4","key":"927_CR7","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.vaccine.2017.11.083","volume":"36","author":"BF Hibbs","year":"2018","unstructured":"Hibbs BF, Miller E, Shi J, Smith K, Lewis P, Shimabukuro TT. Safety of vaccines that have been kept outside of recommended temperatures: Reports to the Vaccine Adverse Event Reporting System (VAERS), 2008\u20132012. Vaccine. 2018;36(4):553\u20138. https:\/\/doi.org\/10.1016\/j.vaccine.2017.11.083.","journal-title":"Vaccine"},{"issue":"11","key":"927_CR8","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1080\/14760584.2016.1182869","volume":"15","author":"J Tomar","year":"2016","unstructured":"Tomar J, Born PA, Frijlink HW, Hinrichs WL. Dry influenza vaccines: towards a stable, effective and convenient alternative to conventional parenteral influenza vaccination. Expert Rev Vaccines. 2016;15(11):1431\u201347. https:\/\/doi.org\/10.1080\/14760584.2016.1182869.","journal-title":"Expert Rev Vaccines"},{"issue":"9","key":"927_CR9","doi-asserted-by":"publisher","first-page":"2886","DOI":"10.1002\/jps.21825","volume":"98","author":"LL Chang","year":"2009","unstructured":"Chang LL, Pikal MJ. Mechanisms of protein stabilization in the solid state. J Pharm Sci. 2009;98(9):2886\u2013908. https:\/\/doi.org\/10.1002\/jps.21825.","journal-title":"J Pharm Sci"},{"key":"927_CR10","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1007\/978-981-13-1244-1_20","volume":"1081","author":"KI Izutsu","year":"2018","unstructured":"Izutsu KI. Applications of freezing and freeze-drying in pharmaceutical formulations. Adv Exp Med Biol. 2018;1081:371\u201383. https:\/\/doi.org\/10.1007\/978-981-13-1244-1_20.","journal-title":"Adv Exp Med Biol"},{"issue":"6","key":"927_CR11","doi-asserted-by":"publisher","first-page":"3836","DOI":"10.1529\/biophysj.103.035519","volume":"86","author":"MT Cicerone","year":"2004","unstructured":"Cicerone MT, Soles CL. Fast dynamics and stabilization of proteins: binary glasses of trehalose and glycerol. Biophys J. 2004;86(6):3836\u201345. https:\/\/doi.org\/10.1529\/biophysj.103.035519.","journal-title":"Biophys J"},{"issue":"6","key":"927_CR12","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1007\/s11095-008-9559-6","volume":"25","author":"JP Amorij","year":"2008","unstructured":"Amorij JP, Huckriede A, Wilschut J, Frijlink HW, Hinrichs WL. Development of stable influenza vaccine powder formulations: challenges and possibilities. Pharm Res. 2008;25(6):1256\u201373. https:\/\/doi.org\/10.1007\/s11095-008-9559-6.","journal-title":"Pharm Res"},{"key":"927_CR13","unstructured":"ISMP. National Vaccine Errors Reporting Program 2017 Analysis (Part I):\u2008Vaccine Errors Continue with Little Change. Institute for Safe Medication Practices. 2018. https:\/\/www.ismp.org\/resources\/ismp-national-vaccine-errors-reporting-program-2017-analysis-part-i-vaccine-errors. Accessed 8 Nov 2020."},{"issue":"4","key":"927_CR14","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1517\/17425247.2014.885947","volume":"11","author":"HS Gill","year":"2014","unstructured":"Gill HS, Kang SM, Quan FS, Compans RW. Cutaneous immunization: an evolving paradigm in influenza vaccines. Expert Opin Drug Deliv. 2014;11(4):615\u201327. https:\/\/doi.org\/10.1517\/17425247.2014.885947.","journal-title":"Expert Opin Drug Deliv"},{"issue":"11","key":"927_CR15","doi-asserted-by":"publisher","first-page":"2975","DOI":"10.1080\/21645515.2016.1171440","volume":"12","author":"S Marshall","year":"2016","unstructured":"Marshall S, Sahm LJ, Moore AC. The success of microneedle-mediated vaccine delivery into skin. Hum Vaccin Immunother. 2016;12(11):2975\u201383. https:\/\/doi.org\/10.1080\/21645515.2016.1171440.","journal-title":"Hum Vaccin Immunother"},{"issue":"11","key":"927_CR16","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.1007\/s11095-017-2223-2","volume":"34","author":"M Leone","year":"2017","unstructured":"Leone M, Monkare J, Bouwstra JA, Kersten G. Dissolving microneedle patches for dermal vaccination. Pharm Res. 2017;34(11):2223\u201340. https:\/\/doi.org\/10.1007\/s11095-017-2223-2.","journal-title":"Pharm Res"},{"issue":"6","key":"927_CR17","doi-asserted-by":"publisher","first-page":"569","DOI":"10.3390\/pharmaceutics12060569","volume":"12","author":"AJ Guillot","year":"2020","unstructured":"Guillot AJ, Cordeiro AS, Donnelly RF, Montesinos MC, Garrigues TM, Melero A. Microneedle-based delivery: an overview of current applications and trends. Pharmaceutics. 2020;12(6):569. https:\/\/doi.org\/10.3390\/pharmaceutics12060569.","journal-title":"Pharmaceutics"},{"key":"927_CR18","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1146\/annurev-chembioeng-060816-101514","volume":"8","author":"MR Prausnitz","year":"2017","unstructured":"Prausnitz MR. Engineering microneedle patches for vaccination and drug delivery to skin. Annu Rev Chem Biomol Eng. 2017;8:177\u2013200. https:\/\/doi.org\/10.1146\/annurev-chembioeng-060816-101514.","journal-title":"Annu Rev Chem Biomol Eng"},{"issue":"16","key":"927_CR19","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1016\/j.vaccine.2014.01.076","volume":"32","author":"JJ Norman","year":"2014","unstructured":"Norman JJ, Arya JM, McClain MA, Frew PM, Meltzer MI, Prausnitz MR. Microneedle patches: usability and acceptability for self-vaccination against influenza. Vaccine. 2014;32(16):1856\u201362. https:\/\/doi.org\/10.1016\/j.vaccine.2014.01.076.","journal-title":"Vaccine"},{"issue":"10095","key":"927_CR20","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/S0140-6736(17)30575-5","volume":"390","author":"NG Rouphael","year":"2017","unstructured":"Rouphael NG, Paine M, Mosley R, Henry S, McAllister DV, Kalluri H, et al. The safety, immunogenicity, and acceptability of inactivated influenza vaccine delivered by microneedle patch (TIV-MNP 2015): a randomised, partly blinded, placebo-controlled, phase 1 trial. Lancet. 2017;390(10095):649\u201358. https:\/\/doi.org\/10.1016\/S0140-6736(17)30575-5.","journal-title":"Lancet"},{"issue":"34","key":"927_CR21","doi-asserted-by":"publisher","first-page":"3389","DOI":"10.1016\/j.vaccine.2013.05.048","volume":"31","author":"BG Weniger","year":"2013","unstructured":"Weniger BG, Glenn GM. Cutaneous vaccination: antigen delivery into or onto the skin. Vaccine. 2013;31(34):3389\u201391. https:\/\/doi.org\/10.1016\/j.vaccine.2013.05.048.","journal-title":"Vaccine"},{"key":"927_CR22","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/978-1-4614-6217-0_13","volume":"785","author":"DG Koutsonanos","year":"2013","unstructured":"Koutsonanos DG, Compans RW, Skountzou I. Targeting the skin for microneedle delivery of influenza vaccine. Adv Exp Med Biol. 2013;785:121\u201332. https:\/\/doi.org\/10.1007\/978-1-4614-6217-0_13.","journal-title":"Adv Exp Med Biol"},{"issue":"3","key":"927_CR23","doi-asserted-by":"publisher","first-page":"e1003024","DOI":"10.1371\/journal.pmed.1003024","volume":"17","author":"AH Forster","year":"2020","unstructured":"Forster AH, Witham K, Depelsenaire ACI, Veitch M, Wells JW, Wheatley A, et al. Safety, tolerability, and immunogenicity of influenza vaccination with a high-density microarray patch: results from a randomized, controlled phase I clinical trial. PLoS Med. 2020;17(3):e1003024. https:\/\/doi.org\/10.1371\/journal.pmed.1003024.","journal-title":"PLoS Med"},{"issue":"2","key":"927_CR24","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.jconrel.2009.10.013","volume":"142","author":"YC Kim","year":"2010","unstructured":"Kim YC, Quan FS, Compans RW, Kang SM, Prausnitz MR. Formulation and coating of microneedles with inactivated influenza virus to improve vaccine stability and immunogenicity. J Control Release. 2010;142(2):187\u201395. https:\/\/doi.org\/10.1016\/j.jconrel.2009.10.013.","journal-title":"J Control Release"},{"issue":"2","key":"927_CR25","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1002\/jps.24283","volume":"104","author":"MJ Mistilis","year":"2015","unstructured":"Mistilis MJ, Bommarius AS, Prausnitz MR. Development of a thermostable microneedle patch for influenza vaccination. J Pharm Sci. 2015;104(2):740\u20139. https:\/\/doi.org\/10.1002\/jps.24283.","journal-title":"J Pharm Sci"},{"issue":"47","key":"927_CR26","doi-asserted-by":"publisher","first-page":"11695","DOI":"10.1021\/ja961869d","volume":"118","author":"K Griebenow","year":"1996","unstructured":"Griebenow K, Klibanov AM. On protein denaturation in aqueous\u2212organic mixtures but not in pure organic solvents. J Am Chem Soc. 1996;118(47):11695\u2013700. https:\/\/doi.org\/10.1021\/ja961869d.","journal-title":"J Am Chem Soc"},{"issue":"1448","key":"927_CR27","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1098\/rstb.2004.1500","volume":"359","author":"CN Pace","year":"2004","unstructured":"Pace CN, Trevino S, Prabhakaran E, Scholtz JM. Protein structure, stability and solubility in water and other solvents. Philos Trans R Soc Lond Ser B Biol Sci. 2004;359(1448):1225\u201335. https:\/\/doi.org\/10.1098\/rstb.2004.1500.","journal-title":"Philos Trans R Soc Lond Ser B Biol Sci"},{"issue":"1","key":"927_CR28","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/J.Ejpb.2008.04.006","volume":"70","author":"H Mok","year":"2008","unstructured":"Mok H, Park TG. Water-free microencapsulation of proteins within PLGA microparticles by spray drying using PEG-assisted protein solubilization technique in organic solvent. Eur J Pharm Biopharm. 2008;70(1):137\u201344. https:\/\/doi.org\/10.1016\/J.Ejpb.2008.04.006.","journal-title":"Eur J Pharm Biopharm"},{"issue":"25","key":"927_CR29","doi-asserted-by":"publisher","first-page":"2930","DOI":"10.1016\/j.vaccine.2015.04.059","volume":"33","author":"A Bonificio","year":"2015","unstructured":"Bonificio A, Ghartey-Tagoe E, Gallorini S, Baudner B, Chen G, Singh P, et al. Fabrication of cell culture-derived influenza vaccine dissolvable microstructures and evaluation of immunogenicity in guinea pigs. Vaccine. 2015;33(25):2930\u20138. https:\/\/doi.org\/10.1016\/j.vaccine.2015.04.059.","journal-title":"Vaccine"},{"issue":"4","key":"927_CR30","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1007\/s13346-015-0228-0","volume":"5","author":"EV Vassilieva","year":"2015","unstructured":"Vassilieva EV, Kalluri H, McAllister D, Taherbhai MT, Esser ES, Pewin WP, et al. Improved immunogenicity of individual influenza vaccine components delivered with a novel dissolving microneedle patch stable at room temperature. Drug Deliv Transl Res. 2015;5(4):360\u201371. https:\/\/doi.org\/10.1007\/s13346-015-0228-0.","journal-title":"Drug Deliv Transl Res"},{"issue":"2","key":"927_CR31","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s13346-016-0282-2","volume":"7","author":"MJ Mistilis","year":"2017","unstructured":"Mistilis MJ, Joyce JC, Esser ES, Skountzou I, Compans RW, Bommarius AS, et al. Long-term stability of influenza vaccine in a dissolving microneedle patch. Drug Deliv Transl Res. 2017;7(2):195\u2013205. https:\/\/doi.org\/10.1007\/s13346-016-0282-2.","journal-title":"Drug Deliv Transl Res"},{"key":"927_CR32","unstructured":"The European Agency for the Evaluation of Medicinal Products (Human Medicines Evaluation Unit) [database on the Internet]. European Medicines Agency. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/note-guidance-harmonisation-requirements-influenza-vaccines_en.pdf. Accessed 23 Jan 2021."},{"issue":"8","key":"927_CR33","doi-asserted-by":"publisher","first-page":"7767","DOI":"10.1016\/J.Actbio.2013.04.045","volume":"9","author":"WC Sun","year":"2013","unstructured":"Sun WC, Araci Z, Inayathullah M, Manickam S, Zhang XX, Bruce MA, et al. Polyvinylpyrrolidone microneedles enable delivery of intact proteins for diagnostic and therapeutic applications. Acta Biomater. 2013;9(8):7767\u201374. https:\/\/doi.org\/10.1016\/J.Actbio.2013.04.045.","journal-title":"Acta Biomater"},{"issue":"5","key":"927_CR34","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1002\/adma.200701205","volume":"20","author":"SP Sullivan","year":"2008","unstructured":"Sullivan SP, Murthy N, Prausnitz MR. Minimally invasive protein delivery with rapidly dissolving polymer microneedles. Adv Mater. 2008;20(5):933\u20138. https:\/\/doi.org\/10.1002\/adma.200701205.","journal-title":"Adv Mater"},{"issue":"5","key":"927_CR35","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1039\/c9tb00912d","volume":"8","author":"J Mao","year":"2020","unstructured":"Mao J, Wang H, Xie Y, Fu Y, Li Y, Liu P, et al. Transdermal delivery of rapamycin with poor water-solubility by dissolving polymeric microneedles for anti-angiogenesis. J Mater Chem B. 2020;8(5):928\u201334. https:\/\/doi.org\/10.1039\/c9tb00912d.","journal-title":"J Mater Chem B"},{"key":"927_CR36","unstructured":"Guideline on Influenza Vaccines (Non-clinical and Clinical Module). In: Health SM. (Ed). United Kingdon: European Medicines Agency, 2016."},{"issue":"1","key":"927_CR37","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s11095-010-0134-6","volume":"28","author":"YC Kim","year":"2011","unstructured":"Kim YC, Quan FS, Compans RW, Kang SM, Prausnitz MR. Stability kinetics of influenza vaccine coated onto microneedles during drying and storage. Pharm Res. 2011;28(1):135\u201344. https:\/\/doi.org\/10.1007\/s11095-010-0134-6.","journal-title":"Pharm Res"},{"key":"927_CR38","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/82_2014_407","volume":"386","author":"I Skountzou","year":"2015","unstructured":"Skountzou I, Compans RW. Skin immunization with influenza vaccines. Curr Top Microbiol Immunol. 2015;386:343\u201369. https:\/\/doi.org\/10.1007\/82_2014_407.","journal-title":"Curr Top Microbiol Immunol"},{"issue":"1","key":"927_CR39","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/nm0103-99","volume":"9","author":"MM Levine","year":"2003","unstructured":"Levine MM. Can needle-free administration of vaccines become the norm in global immunization? Nat Med. 2003;9(1):99\u2013103. https:\/\/doi.org\/10.1038\/nm0103-99.","journal-title":"Nat Med"},{"key":"927_CR40","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.jconrel.2015.11.019","volume":"240","author":"J Arya","year":"2016","unstructured":"Arya J, Prausnitz MR. Microneedle patches for vaccination in developing countries. J Control Release. 2016;240:135\u201341. https:\/\/doi.org\/10.1016\/j.jconrel.2015.11.019.","journal-title":"J Control Release"},{"issue":"45","key":"927_CR41","doi-asserted-by":"publisher","first-page":"7175","DOI":"10.1016\/j.vaccine.2020.07.064","volume":"38","author":"PM Frew","year":"2020","unstructured":"Frew PM, Paine MB, Rouphael N, Schamel J, Chung Y, Mulligan MJ, et al. Acceptability of an inactivated influenza vaccine delivered by microneedle patch: Results from a phase I clinical trial of safety, reactogenicity, and immunogenicity. Vaccine. 2020;38(45):7175\u201381. https:\/\/doi.org\/10.1016\/j.vaccine.2020.07.064.","journal-title":"Vaccine"},{"issue":"37","key":"927_CR42","doi-asserted-by":"publisher","first-page":"4727","DOI":"10.1016\/j.vaccine.2015.02.076","volume":"33","author":"BY Lee","year":"2015","unstructured":"Lee BY, Bartsch SM, Mvundura M, Jarrahian C, Zapf KM, Marinan K, et al. An economic model assessing the value of microneedle patch delivery of the seasonal influenza vaccine. Vaccine. 2015;33(37):4727\u201336. https:\/\/doi.org\/10.1016\/j.vaccine.2015.02.076.","journal-title":"Vaccine"},{"issue":"12","key":"927_CR43","doi-asserted-by":"publisher","first-page":"e0169030","DOI":"10.1371\/journal.pone.0169030","volume":"11","author":"C Wong","year":"2016","unstructured":"Wong C, Jiang M, You JH. Potential cost-effectiveness of an influenza vaccination program offering microneedle patch for vaccine delivery in children. PLoS One. 2016;11(12):e0169030. https:\/\/doi.org\/10.1371\/journal.pone.0169030.","journal-title":"PLoS One"}],"container-title":["Drug Delivery and Translational Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-021-00927-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13346-021-00927-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-021-00927-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,23]],"date-time":"2021-03-23T15:20:30Z","timestamp":1616512830000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13346-021-00927-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,15]]},"references-count":43,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["927"],"URL":"https:\/\/doi.org\/10.1007\/s13346-021-00927-4","relation":{},"ISSN":["2190-393X","2190-3948"],"issn-type":[{"value":"2190-393X","type":"print"},{"value":"2190-3948","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,15]]},"assertion":[{"value":"26 January 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All institutional and national guidelines for the care and use of laboratory animals were followed.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Mark Prausnitz serves as a consultant to companies, is a founding shareholder of companies, and is an inventor on patents licensed to companies developing microneedle-based products (Micron Biomedical). These potential conflicts of interest have been disclosed and are managed by Georgia Tech.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}